Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00656448 · ClinicalTrials.gov registry record · Phase 3
A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 51
- Enrollment target
NCT00656448: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00656448 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 51 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00656448, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) and are receiving chemotherapy. Researchers also want to learn about the remission rates (rates of recovery) in patients with cancer who have received treatment with epoetin alfa. The safety and effectiveness of this therapy will also be studied.
Interventions
- DRUG Procrit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00656448
The ClinicalTrials.gov registry entry for NCT00656448 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Procrit is the first listed.
NCT00656448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00656448 about?
NCT00656448 is a clinical study titled "A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS". The goal of this clinical research study is to find out if Procrit (epoetin alfa) will help decrease the need for blood transfusions in patients who have Acute Myelogenous Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) and are receiving chemotherapy. Researchers also want to learn about ...
What is the current status of trial NCT00656448?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 51 participants. The study started on 2008-03. Estimated completion is 2013-06.
What interventions are being tested in trial NCT00656448?
The interventions under investigation include: Procrit (DRUG).
Who is sponsoring clinical trial NCT00656448?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.